Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: A prospective cohort study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Neirynck, Nathalie ^a   Glorieux, Griet ^a   Schepers, Eva ^a   Verbeke, Francis ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; DEATH; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; VERY ELDERLY; CHRONIC KIDNEY FAILURE; DISEASE COURSE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84926342396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122073     Document Type: Article

References (31)

1. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. J Am Soc Nephrol. 2004; 15: 1307-15. PMID: 15100371
2. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010; 77: 550-6. doi: 10.1038/ki.2009.503 PMID: 20016471
3. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease-Comparison of traditional and novel risk factors. Jama-Journal of the American Medical Association. 2005; 293: 1737-45. PMID: 15827312
4. Goicoechea M, Quiroga B, García de Vinuesa S, Verdalles Ü, Reque J, Panizo N, et al. Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease. Ren Fail. 2012; 34: 1002-9. doi: 10.3109/0886022X.2012.696469 PMID: 22746155
5. Soriano S, Gonzalez L, Martin-Malo A, Rodriguez M, Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol. 2007; 67: 352-7. PMID: 17598370
6. Meuwese CL, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, Qureshi AR, et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant. 2011; 26: 1313-8. doi: 10.1093/ndt/gfq557 PMID: 20846939
7. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005; 16 Suppl 1: S83-S88. PMID: 15938042
8. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 1154-60. PMID: 14993508
9. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signall. 2012; 24: 1297-305. doi: 10.1016/j.cellsig.2012.02.006 PMID: 22374304
10. Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem. 2008; 283: 14177-81. doi: 10.1074/jbc.R700052200 PMID: 18385130
11. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al. Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J Am Soc Nephrol. 2012; 23: 516-24. doi: 10.1681/ASN.2011060628 PMID: 22266664
12. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, et al. Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. J Am Soc Nephrology. 2012; 23: 507-15. doi: 10.1681/ASN.2011060627 PMID: 22266663
13. Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C, et al. Association of Serum Concentration of TNFR1 With All-Cause Mortality in Patients With Type 2 Diabetes and Chronic Kidney Disease: Follow-up of the SURDIAGENE Cohort. Diabetes Care. 2014; 37: 1425-31. doi: 10.2337/dc13-2580 PMID: 24623026
14. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68: 237-45. PMID: 15954913
15. Levey AS, Stevens LA, Schmid CH, Zhang YP, Castro AF, Feldman HI et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009; 150: 604-13. PMID: 19414839
16. Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, et al. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A. 1990; 87: 8331-5. PMID: 2172983
17. Bemelmans MHA, Gouma DJ, Buurman WA. Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine. 1994; 6: 608-15. PMID: 7893969
18. Pinckard JK, Sheehan KC, Arthur CD, Schreiber RD. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol. 1997; 158: 3869-73. PMID: 9103455
19. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol. 2004; 15: 1897-903. PMID: 15213279
20. Luna JM, Moon Y, Liu K, Spitalnik S, Paik M, Sacco R, et al. Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: the Northern Manhattan Study. Age Ageing. 2013; 42: 385-90. doi: 10.1093/ageing/afs175 PMID: 23321203
21. Schnabel RB, Yin X, Larson MG, Yamamoto JF, Fontes JD, Kathiresan S, et al. Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol. 2013; 33: 1728-33. doi: 10.1161/ATVBAHA.112.301174 PMID: 23640499
22. Nilsson L, Szymanowski A, Swahn E, Jonasson L. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS ONE. 2013; 8: e55477. doi: 10.1371/journal.pone.0055477 PMID: 23405158
23. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation. 2005; 111: 863-70. PMID: 15699251
24. Ueland T, Kjekshus J, Froland SS, Omland T, Squire IB, Gullestad L, et al. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. J Am Coll Cardiol. 2005; 46: 2018-21. PMID: 16325035
25. Leeuwenberg JF, Jeunhomme TM, Buurman WA. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol. 1994; 152: 4036-43. PMID: 8144970
26. Obregon C, Rothen-Rutishauser B, Gerber P, Gehr P, Nicod LP. Active uptake of dendritic cell-derived exovesicles by epithelial cells induces the release of inflammatory mediators through a TNF-alpha-mediated pathway. Am J Pathol. 2009; 175: 696-705. doi: 10.2353/ajpath.2009.080716 PMID: 19628765
27. Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, Kaler M, et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A. 2004; 101: 1297-302. PMID: 14745008
28. Aderka D, Sorkine P, bu-Abid S, Lev D, Setton A, Cope AP, et al. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest. 1998; 101: 650-9. PMID: 9449699
29. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004; 200: 367-76. PMID: 15289505
30. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992; 89: 4845-9. PMID: 1317575
31. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992; 175: 323-9. PMID: 1310100